Contents

Volume 73 Issue 1 | ARD January 2014

Editorial
1 Classification criteria for Sjögren’s syndrome: nothing ever stands still
S J Bowman, R I Fox

Viewpoint
3 Proposal for a new nomenclature of disease-modifying antirheumatic drugs
J S Smolen, D van der Heijde, K P Machold, D Aletaha, R Landewé

Recommendations
6 Treating spondyloarthritides, including ankylosing spondylitis and psoriatic arthritis, to target: recommendations of an international task force

17 International recommendations for the assessment of autoantibodies to cellular antigens referred to as anti-nuclear antibodies

Review
24 Hepatitis C virus-induced vasculitis: therapeutic options
P Carabba, B Terrier, D Saadoun

Clinical and epidemiological research
31 Comparison of the American-European Consensus Group Sjögren’s syndrome classification criteria to newly proposed American College of Rheumatology group criteria in a large, carefully characterised sicca cohort

39 Efficacy of certolizumab pegol on signs and symptoms of axial spondyloarthritis including ankylosing spondylitis: 24-week results of a double-blind randomised placebo-controlled Phase 3 study
R Landewé, J Basun, A Descartes, M Dougados, W P Alkemper, P J Mease, J De Reville, M Rudwaleit, D van der Heijde, C Stich, B Hoepeken, A Fideler, C Content, M de Longueville, J Stiper

48 Effect of certolizumab pegol on signs and symptoms in patients with psoriatic arthritis: 24-week results of a Phase 3 double-blind randomised placebo-controlled study (RAPID-PsA)
P J Mease, R Fleischmann, A A Descartes, J Willenbohr, M Khanish, D Kadar, P Witham, C Stich, B Hoepeken, T Arledge, D van der Heijde

56 Treatment of diffuse systemic sclerosis with hyperimmune caprine serum (AIMSPRO): a phase II double-blind placebo-controlled trial
N P Quillinan, D McIntosh, J Vernes, S Haq, C P Denton

62 Prevalence of comorbidities in rheumatoid arthritis and evaluation of their monitoring: results of an international, cross-sectional study (COMORA)

69 A randomised, double-blind, parallel-group study of the safety and efficacy of subcutaneous tocilizumab versus intravenous tocilizumab in combination with traditional disease-modifying antirheumatic drugs in patients with moderate to severe rheumatoid arthritis (SUMMACTA study)
G B Burmester, A Rubbers-Roth, A Caragnag, S Hall, P Leszczynski, D Feldman, M J Ronaghi, G Roeste, C Ludovico, P Lu, J Rowell, M Ray, E F. Myllär

75 Remission induction comparing infliximab and high-dose intravenous steroid, followed by treat-to-target: a double-blind, randomised, controlled trial in new-onset, treatment-naive, rheumatoid arthritis (the IDEA study)

86 Head-to-head comparison of subcutaneous abatacept versus adalimumab for rheumatoid arthritis: two-year efficacy and safety findings from AMPLÉ trial
M Schiff, M E Weintz, R Valente, D van der Heijde, G Cieres, A Elegrée, M Maldonado, R Fleischmann

95 Assessment of short-term symptomatic efficacy of tocilizumab in ankylosing spondylitis: results of randomised, placebo-controlled trials
J Stiper, B Porter-Brown, L Thompson, O Harast, M Dougados

MORE CONTENTS ▶
Contents

Volume 73 Issue 1 | ARD January 2014

101 Efficacy and safety of infliximab plus naproxen versus naproxen alone in patients with early, active axial spondyloarthritis: results from the double-blind, placebo-controlled INFAST study, Part 1
J Spaepen, J Lenaerts, J Wollenhaupt, M Rudwaleit, V I Mazzuero, L Myasoedova, S Park, Y Song, R Yao, D Chitkara, N Vastagteije, on Behalf of All INFAST Investigators

108 Maintenance of biologic-free remission with naproxen or no treatment in patients with early, active axial spondyloarthritis: results from a 6-month, randomised, open-label follow-up study, INFAST Part 2
J Spaepen, J Lenaerts, J Wollenhaupt, M Rudwaleit, V I Mazzuero, L Myasoedova, S Park, Y Song, R Yao, D Chitkara, N Vastagteije, on Behalf of All INFAST Investigators

114 Performance of the 2010 ACR/EULAR classification criteria for rheumatoid arthritis: a systematic literature review
H Radner, Y Neogi, J S Smolen, D Alkaza

124 Open-label tofacitinib and double-blind atorvastatin in rheumatoid arthritis patients: a randomised study

132 The role of methotrexate co-medication in TNF-inhibitor treatment in patients with psoriatic arthritis: results from 440 patients included in the NOR-DMARD study
A S Lexberg, E Rødevand, S Kalstad, K Mikkelsen, T K Okten

138 Lymphoma risk in systemic lupus: effects of disease activity versus treatment

143 Risk of mortality in patients with psoriatic arthritis, rheumatoid arthritis and psoriasis: a longitudinal cohort study

154 Annual direct medical cost of active systemic lupus erythematosus in five European countries
A Dore, Z Amarnia, R Cervera, M A Khawamthia, M Schneider, J Richter, F Guillet, G Kubler, F Maurel, A Gorgianov, A Pernot, M Murray, C Schmidt, I Boucot

161 Effects of golimumab, an anti-tumour necrosis factor-α human monoclonal antibody, on lipids and markers of inflammation
O Nived, M A Petri, S Jacobsen, S Manzi, E M Ginzler

170 MicroRNA-146a and Ets-1 gene polymorphisms in ocular Behçet’s disease and Vogt–Koyanagi–Harada syndrome
Q Zhou, S Han, L Liang, Z Li, X Tan, L Wei, B Lei, A Kijima, P Yang

177 Tophaceous gout and high level of hyperuricaemia are both associated with increased risk of mortality in patients with gout
F Perez-Ruiz, I Martinez-Indurain, I Carmona, A M Herrero-Buitrón, J J Pigado, E Krohn

183 Efficacy and safety of epratuzumab in patients with moderate/severe active systemic lupus erythematosus: results from EMBLEM, a phase IIb, randomised, double-blind, placebo-controlled, multicentre study

191 Expert consensus for performing right heart catheterisation for suspected pulmonary arterial hypertension in systemic sclerosis: a Delphi consensus study with cluster analysis
I Avouac, D Haschke, D E Fast, C F Opitz, O Destrée, Y Allamore, for the EPOSS group

207 The characterisation and determinants of quality of life in ANCA associated vasculitis

212 International comparisons of the consultation prevalence of musculoskeletal conditions using population-based healthcare data from England and Sweden

219 Using lifestyle factors to identify individuals at higher risk of inflammatory polyarthritis (results from the European Prospective Investigation of Cancer-Norfolk and the Norfolk Arthritis Register—the EPIC-2-NOAR Study)
M Luther, R N Luben, C Morgan, D K Buen, T Marshall, M Lunt, S M M Vranspe, D P M Symmons, T K Khaw, N Wareham, J N Bruce

227 Patients with non-Jo-1 anti-tRNA-synthetase autoantibodies have worse survival than Jo-1 positive patients
R Aggarwal, E Cassidy, N Ferrig, D C Koontz, M Lucas, D P Ascherman, C V Oddis

233 Effect of different imputation approaches on the evaluation of radiographic progression in patients with psoriatic arthritis: results of the RAPID-PsA 24-week phase III double-blind randomised placebo-controlled study of certolizumab pegol
D van der Heijde, R Fleischmann, J Wollenhaupt, A Deodhar, D Kielar, F Wolter, C Stach, B Hoepken, T Arelage, P J van der Heijde

238 Treating axial and peripheral spondyloarthritis, including psoriatic arthritis, to target: results of a systematic literature search to support an international treat-to-target recommendation in spondyloarthritis
M M Schools, J Braun, M Dougados, P Emery, O Fitzgerald, A Kavanagh, T K Okten, R Lundeven, T Lugat, P Mease, J Ollivier, J Reveil, C Pettit, C Rudwaleit, J Steep, J S Smolen, M de Wit, D van der Heijde
Basic and translational research

The risk of gastrointestinal perforations in patients with rheumatoid arthritis treated with anti-TNF therapy: results from the BSRBR-RA

256 A phase 1b clinical trial evaluating sifalimumab, an anti-IFN-α monoclonal antibody, shows target neutralisation of a type I IFN signature in blood of dermatomyositis and polymyositis patients
B W Higgins, W Zhu, C Akeredo, W I White, P Brokaw, X Guo, M Rebeletus, C Le, A Amato, D Fiorentino, S A Greenberg, J Drappa, L Richth, W Jallah, Y Yao

258 Contribution of the COMT Val158Met variant to symptomatic knee osteoarthritis

263 Heightened immune response to autotollinated Porphyromonas gingivalis peptidylarginine deiminase: a potential mechanism for breaching immunologic tolerance in rheumatoid arthritis

270 Low-avidity anticitrullinated protein antibodies (ACPA) are associated with a higher rate of joint destruction in rheumatoid arthritis
P Swannala, K Bessemare, R Kuecle, H U Scherer, E W N Levarth, A H van der Helm-van Mil, D van Schaardenburg, T W J Huizinga, E M Toes, L A Trouw

277 Urinary CD4+ T cells identify SLE patients with proliferative lupus nephritis and can be used to monitor treatment response
P Englund, C Bader, K Koryczeski, J R Loeke, R Undeutsch, R Buscar, D Dragun, M Cools, U Schneider, K Ausperts, J Y Humrich, F Hiepe, M Backhaus, A H Radbruch, G R Bumester, G Bromekeisen

284 Ochronotic osteoarthropathy in a mouse model of alkaptonuria, and its inhibition by nitisinone
A J Preston, C M Keenan, H Sutherland, P J Wilson, B Wilkenski, A M Taylor, D P Williams, L R Ranganath, J A Gallaghcr, J C Jarvis

290 Identification of a new exon 2-skipped TNFR1 transcript: regulation by three functional polymorphisms of the TNFR-associated periodic syndrome (TRAPS) gene
C Kinke, E Sanchez, S Soler, M Banas-Howari, M Albers, L Ohi, M F Mcdonald, I Touw, S Grandemange

298 Lysophosphatidic acid receptor inhibition as a new multipronged treatment for rheumatoid arthritis
B Orosa, S Garcia, P Martinez, A Gonzalez, J J Gomez-Reino, C Comol

306 IL-7 receptor α expressing B cells act proinflammatory in collagen-induced arthritis and are inhibited by sympathetic neurotransmitters
G Pongratz, J M Anderle, M Medier, S Anders, S Grauel, R H Straub

Letters

313 Population-specific effects of SLC17A1 genotype on serum urate concentrations and renal excretion of uric acid during a fructose load
N Dalbeth, M E House, G D Camble, A Home, J Purvis, A Stewart, M Ferrer, M Cadzow, A Phipps-Green, T R Merriman

315 Contribution of the COMT Val158Met variant to symptomatic knee osteoarthritis

317 Association of medication beliefs and self-efficacy with adherence in urban Hispanic and African-American rheumatoid arthritis patients

318 Disease assessment in psoriatic spectrum: a modular approach for use in routine clinical practice
J Wajed, P Helliwell, E Korendowych, K Cashley, S Oliver, L Parnich, B Kirnham

Miscellaneous

320 Correction

Electronic pages

e1 Is TNF-α really involved in giant cell arteritis pathogenesis?
M Samson, S Audia, N Jankestawdi, B Bonnete

e2 Impact of gender on outcomes in ankylosing spondylitis
E Feldtkeller, G Lind-Albrecht

e3 Response to: ‘Impact of gender on outcomes in ankylosing spondylitis’ by Feldtkeller et al
I van der Horst-Bruinsma, D Zank, A Szumski, A S Koenig

e4 Biologic discontinuation studies: a systematic review of methods; comment on the article by Yoshida et al
A van der Alst, N van Hertwaarde, A A den Broeder

e5 Response to: ‘Biologic discontinuation studies: a systematic review of methods’ by van der Alst et al
K Yoshida, Y-K Sung, A Kavanagh, S-C Bae, M E Wibratan, M Koshimoto, K Mansa, S Tohma, D H Solomon